Emerging therapies in pediatric atopic dermatitis patients

• Published in: Dermatological reviews 2022-02, Vol.3 (1), p.29-33
• Main Authors: Bowles, Alexandra, Logas, Christopher M., Glick, Brad P., Del Rosso, James Q.
• Format: Article
• Language: English
• Subjects: atopic; dermatitis; new therapies; pediatrics
• ISSN: 2637-7489; 2637-7489
• DOI: 10.1002/der2.115

Pediatric atopic dermatitis (AD) is a difficult disease to treat and novel treatments, both topical and systemic, are continuously being investigated. The current approved treatments for pediatric AD include topical anti‐inflammatory therapies such as topical corticosteroids, topical calcineurin inhibitors, and topical phosphodiesterase 4 inhibitors. Current systemic therapies approve for pediatric patients of various ages include dupilumab, cyclosporine, azathioprine, methotrexate, and mycophenolate mofetil. While these treatments have been used for many years, the efficacy and safety of these medications have been questioned. Currently, there are multiple ongoing investigational studies looking at various topical and systemic treatments that have promising results for the pediatric population, even those as young as 6 months of age. Pediatric atopic dermatitis management is constantly evolving, and physicians should be aware of current studies and approved regimens to provide their patient's with the best care.